Monitoring the effect of belinostat in solid tumors by H4 acetylation

Histone deacetylase (HDAC) inhibition is a novel entity in medical oncology, and several HDAC inhibitors are in clinical trials. One of them is the hydroxamic acid belinostat (PXD101) that has demonstrated therapeutic efficacy for several clinical indications. Acetylation of histones is a key event...

Descripción completa

Detalles Bibliográficos
Autores principales: MARQUARD, LENA, PETERSEN, KAMILLE DUMONG, PERSSON, MORTEN, HOFF, KIRSTEN DAMGAARD, JENSEN, PETER BUHL, SEHESTED, MAXWELL
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2008
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774150/
https://www.ncbi.nlm.nih.gov/pubmed/18452428
http://dx.doi.org/10.1111/j.1600-0463.2008.00957.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2774150/
https://www.ncbi.nlm.nih.gov/pubmed/18452428
http://dx.doi.org/10.1111/j.1600-0463.2008.00957.x

Ejemplares similares